Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.

@article{Brooks2002ArvanilinducedIO,
  title={Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.},
  author={Jason W Brooks and Gareth Pryce and Tiziana Bisogno and Sian Isobel Jaggar and Deborah J R Hankey and Peter de Nully Brown and Daniel Bridges and Catherine A. Ledent and Maurizio Bifulco and Andrew C. Rice and Vincenzo Di Marzo and David Baker},
  journal={European journal of pharmacology},
  year={2002},
  volume={439 1-3},
  pages={83-92}
}
Activation of cannabinoid receptors causes inhibition of spasticity, in a mouse model of multiple sclerosis, and of persistent pain, in the rat formalin test. The endocannabinoid anandamide inhibits spasticity and persistent pain. It not only binds to cannabinoid receptors but is also a full agonist at vanilloid receptors of type 1 (VR1). We found here that vanilloid VR1 receptor agonists (capsaicin and N-N'-(3-methoxy-4-aminoethoxy-benzyl)-(4-tert-butyl-benzyl)-urea [SDZ-249-665]) exhibit a… CONTINUE READING
26 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…